Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
A phase 2 trial of Envafolimab, Lenvatinib in endometrial cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.
Overview
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer is a phase 2 interventional study registered as NCT05112991 by 3D Medicines (Sichuan) Co., Ltd., with 108 participants planned, started 2022-03-04 and due to reach its primary completion in 2026-12. Interventions recorded: Envafolimab+Lenvatinib, Envafolimab. Conditions listed: Advanced Endometrial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Shares Envafolimab, Lenvatinib.
- TrialA Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Shares Lenvatinib, Endometrial cancer.
- TrialKEYNOTE-775 / Study 309
Shares Lenvatinib, Endometrial cancer.
- PairingLenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)
Shares Lenvatinib, Endometrial cancer.
- PathwayEndometrial cancer (KEGG map)
Shares Lenvatinib, Endometrial cancer.
- CompanyEisai
Shares Lenvatinib, Endometrial cancer.